Hemp farmers, producers, manufacturers and processors, including those in tribal communities, told a Senate panel they are eagerly awaiting FDA’s next move on regulating cannabis-based products, namely those containing cannabidiol (CBD) derived from hemp, as those regulatory steps will drive the market. FDA Principal Deputy Commissioner Amy Abernethy outlined the challenges FDA faces in crafting a regulatory framework and pathway for CBD derived from hemp at a Senate agriculture committee hearing Thursday (July 25). One of FDA’s main tasks is...